In Dec. 2017, Robert Russell brought donuts to the nurses on all three wards of the ninth floor of Duke Hospital — his tradition for the past three years. He says it’s the least he can do for those who saw him through the “scariest” couple weeks of his life, which began with an HPV-associated tonsil cancer diagnosis.
Tough Love And Healing For Tonsil Cancer Survivor
Published
From the Duke Cancer Institute archives. Content may be out of date.
In December 2017 Robert Russell brought donuts to the nurses on all three wards of the ninth floor of Duke Medical Center — something he’s been doing regularly for the past three years. He started the tradition because he says it’s the least he can do for those who saw him through the “scariest” couple weeks of his life.
In July 2014, at age 52, Russell was diagnosed by Duke surgical oncologist Ramon Esclamado, MD, with advanced-stage human papilloma virus (HPV) associated squamous cell carcinoma of the oropharynx.
The oropharynx is the middle part of the throat, which includes the soft palate, the base of the tongue, the tonsils, and the side and back wall of the throat.
The first symptoms of oropharynx cancer are typically a lump in the neck, a sore throat and/or ear pain although oropharynx cancer can also be asymptomatic. Physicians say self-awareness and regular visits to the dentist, who does a thorough oral exam, are key to early detection.
Russell had a sore throat and had been coughing up blood for six or seven months by the time he was diagnosed. When his symptoms didn’t go away, following visits to two different primary care physicians, he had asked his wife to look down his throat.
“I think she passed out,” he recounted. “My tonsil was hanging inward and my throat was in bad shape. I went to my ENT doctor the very next day and he said he thought it was cancer, but not bad cancer, and referred me to Duke.”
Tough Love
Esclamado, radiation oncologist David Brizel, MD, and medical oncologist Frank Dunphy, MD, (now retired) initiated an intensive 7 week treatment plan consisting of radiotherapy and concurrent chemotherapy.
However, part-way through this outpatient regimen— Russell, increasingly weak, began battling nausea and loss of taste.. He was admitted to the hospital to help manage his symptoms and continued with his treatment during this period.
“It was to the point where I was asked, a few times, if I wanted to talk to a preacher and I finally said yes,” Russell, a father of three, said. “That was scary. I believe in God, but I wasn’t sure what God thought about me.”
He completed therapy, returned home in September 2014 and was scheduled for regular follow-ups. He went back to work at his two jobs that December — selling Hondas and Atlantic Breeze shutters — but something wasn’t right. His throat and tongue was so raw it burned, he still had no sense of taste, and he didn’t want to eat.
“The first time I went back to see Dr. Brizel for a follow-up, he said ‘Robert, your cancer is gone, but if you don’t eat, you’re going to die, and everything that you’ve gone through will have been in vain,’” Russell recalled.
“Deep-Sea” Healing
Russell, who describes himself as “hard-headed,” said Brizel’s “tough love” message got through. He started eating again, but couldn’t gain weight, so Brizel advised a feeding tube. Brizel also recommended Russell try hyperbaric oxygen — a unique therapy that uses pressurized oxygen to enhance the healing of the irradiated tissues in his pharynx that were not healing well.
“If that didn’t work, I may have needed surgery,” said Russell, who ended up making the “dives” in a The Duke Hyperbaric Chamber, at a pressure equivalent of being under 33 feet of sea water, twice-a-day for 35 days. “Thank God it worked.”
About a week after he returned home, his pain largely went away and he got his sense of taste and appetite back.
Rising Cases
While the HPV-associated oropharynx cancer that Russell survived remains a relatively rare cancer in the United States, it’s now constitutes the most common type of head and neck cancer and the number of cases is rising, some say to epidemic proportions.
As many as 80 percent of oropharynx cancer cases, like Russell’s, are caused by HPV, the most common sexually transmitted infection in the country. Actor Michael Douglas made headlines when he announced in 2013 that he had treated for HPV-associated oropharynx cancer in 2010.
Most HPV-associated oropharynx cancer patients that Brizel and his colleagues see at Duke are relatively young and male; in their 40s to mid 50s, with some in their late 30s. More males than females, by a ratio of four to one, get this cancer according to the Centers for Disease Control and Prevention, which estimated that about 13,200 new cases are diagnosed in men and 3,200 in women each year nationwide. Importantly, this disease is not associated with smoking.
It takes many years for an HPV infection to result in cancer, if it does at all, explained Brizel, who co-directs the Duke Cancer Head & Neck Cancer Program.
“The changes happen at a cellular level and you go from pre-cancer to a cancerous condition,” said Brizel. “The overwhelming majority of people who get infected with HPV clear it from their immune system. A small proportion of people don’t, and they are the ones who go on to develop the disease.”
Brizel said there’s some data suggesting that the reason more men than women get HPV-associated oropharynx cancer is because not all men mount as vigorous of an immune response as women, though nobody really knows why that is.
The HPV-associated oropharynx patients Brizel sees are too old to have had access to any of the new HPV vaccines, the first of which hit the market in 2006. While the vaccination is indicated up to age 26, the American Cancer Society currently recommends routine HPV vaccination for females and males starting at age 11 or 12 years — before they are sexually active — to protect against HPV infections that can could eventually lead to several cancers and pre-cancers. In addition to oropharynx cancer, various strains of HPV can cause cancers of the cervix, vagina, vulva, and anus, and the vaccine effectively protects against these diseases too.
The vaccine can be “nearly 100 percent effective” against HPV-associated oropharynx cancer, Brizel said, if given before teens are sexually active.
Evolving Treatment
Standard-of-care treatment for oropharynx cancer, meanwhile, is still evolving, said Brizel. Depending on the stage and extent of the disease, patients may be treated with radiotherapy and chemotherapy, like Russell was, but some may be well-treated with radiation alone, and some may be treated adequately with surgery alone or surgery and radiation without chemotherapy.
Oropharynx cancer that’s associated with HPV usually has a very favorable prognosis, more so than many other types of head and neck cancers and other cancers in general, said Brizel, with tumors less likely to recur than those not linked to HPV infection.
“Because the prognosis is very good and conventional therapies are extraordinarily effective, recent efforts have been focused on trying to figure out how to reduce the intensity of therapy so that we can reduce negative side effects of treatment — which is what Robert Russell had — without compromising the effectiveness of the cancer treatment,” said Brizel.
For example, Brizel and his team are now looking at the use of PET scanning during treatment to see if they can identify patients that don’t need as much radiation or chemotherapy. And they’re currently conducting a trial with a radiation protective drug that was developed at Duke to reduce some of the side effects of treatment.
Russell has been cancer-free for three years. He’s gained all his weight back, and eats pretty normally now, though he has to drink a lot of water. He has lingering tinnitus in his ear, a side-effect of his chemotherapy. He continues to enjoy a good game of golf and walks on the beach. He also said that with his physical appearance slightly altered by the disease he’s “not as confident as he used to be.”
The good news, he said, is that his care team has told him he can be “cautiously optimistic” about his prognosis.
“All my doctors were just amazing,” he said, adding that he also appreciated the hugs he got from the lady at the check-in counter, the gospel songs sung by the parking garage attendant, the church volunteers at Caring House who served him “the best meal of his life” (mashed potatoes), and of course, those ninth floor nurses.
“I actually enjoy going back to Duke, since I found out I was ok,” said Russell, who returns for follow-ups every six months. “And I like talking about my experience now because I know I’m lucky to be here and I want people to know.”
Researchers at the Duke Cancer Institute (DCI) are working with collaborators at leading academic medical centers to explore a faster, less invasive way to detect and analyze head and neck cancers using light and artificial intelligence.In a recent study published in Biophotonics Discovery, a DCI team led by Tuan Vo-Dinh, PhD, partnered with Maie St John, MD, and clinical researchers at the University of California, Los Angeles (UCLA), to demonstrate how a light-based imaging technique combined with machine learning could help distinguish cancerous tissue with high accuracy. The work is now continuing at Johns Hopkins University.Today, diagnosing many cancers such as thyroid and head and neck cancers often relies on pathology or fine needle aspiration (FNA). In an FNA procedure, a thin needle is inserted into a tumor to collect cells, which are then analyzed by a pathologist.“While these approaches are widely used, they can be time-consuming and don’t always give clear or definitive results,” Vo-Dinh said. “In some cases, patients may have to wait weeks for answers, and the accuracy can vary depending on sampling and interpretation.”The collaborative teams used a technology known as Dynamic Optical Contrast Imaging (DOCI), a technique developed at UCLA, which uses laser light to excite tissue. When exposed to this light, different molecules in the tissue emit fluorescence—subtle signals that vary depending on whether tissue is cancerous or healthy. The result is a color-coded “map” of the tissue that reflects its biological properties.“Instead of looking at one spot on the tissue sample, this technique provides spatial information across the entire tissue region monitored,” Vo-Dinh explained. “You can actually see differences in how cancerous and non-cancerous areas respond to light.”These light-based signals are incredibly rich—but also complex. That’s where machine learning comes in. Vo-Dinh’s team applied machine learning algorithms to analyze the complex imaging data generated by DOCI. The researchers trained AI models to recognize subtle patterns in the imaging data and distinguish between different types of thyroid cancer, specifically papillary and follicular thyroid cancers, and to determine whether tissue was cancerous.The results were promising. The machine learning system showed strong agreement with pathological findings, accurately identifying cancerous regions within the tissue samples.“This is an exciting proof of principle demonstration that combining photonics with AI can work together and provide meaningful, reliable answers,” Vo-Dinh said. “The performance we’re seeing so far is very encouraging.”While the research is still in its early stages, the potential implications for patient care are significant.Because this approach directly analyzes the tissue and does not rely on waiting for lab-based assays, it could eventually support faster, point-of-care cancer assessment. Imagine a future where clinicians may be able to use similar tools directly on tissue, potentially even during surgery, to guide decisions in real time.“It could reduce the need for repeat biopsies and long waiting periods,” Vo-Dinh said. “And because the technique is non-invasive, it may also make screening easier and more accessible for patients.”The work underscores the critical importance of collaboration across institutions and disciplines, bringing together clinical expertise, advanced imaging, and data science.“This is a very synergistic partnership,” Vo-Dinh said. “Each group contributes something essential, from clinical insight to optical technology to computational analysis. That kind of complementarity is what drives innovation.”Next steps will focus on expanding and refining the technology, with the goal of enabling real-time, in situ cancer detection.“We’re excited to continue this collaboration and explore how far this approach can go,” Vo-Dinh said.
The Duke Cancer Institute Supportive Care and Survivorship Center is hosting a new Head & Neck Cancer Support Group. This group is designed to provide a structured and supportive environment for patients and caregivers to connect, share experiences, and access peer-informed resources as part of comprehensive, holistic cancer care.The Head & Neck Cancer Support Group will meet on the second Monday of each month. Geoff Vaughan, a licensed medical family therapist with DCI, will facility these sessions. A medical student-based patient navigation component is currently being developed and will launch in spring 2026.This initiative is supported by the Albert Schweitzer Fellowship, North Carolina Chapter (2025–2026), awarded to Rebecca Zasloff and Alie Hunter, medical students at Duke University School of Medicine and members of the Transdisciplinary Otolaryngology Research, Community Health, and Equity (TORCHE) Lab led by Nosayaba Osazuwa-Peters, PhD. The project has also recently received Duke Bass Connections funding for the 2026–2027 academic year, which will support the continuation and expansion of this work.
Researchers at the Duke Cancer Institute (DCI) are working with collaborators at leading academic medical centers to explore a faster, less invasive way to detect and analyze head and neck cancers using light and artificial intelligence.In a recent study published in Biophotonics Discovery, a DCI team led by Tuan Vo-Dinh, PhD, partnered with Maie St John, MD, and clinical researchers at the University of California, Los Angeles (UCLA), to demonstrate how a light-based imaging technique combined with machine learning could help distinguish cancerous tissue with high accuracy. The work is now continuing at Johns Hopkins University.Today, diagnosing many cancers such as thyroid and head and neck cancers often relies on pathology or fine needle aspiration (FNA). In an FNA procedure, a thin needle is inserted into a tumor to collect cells, which are then analyzed by a pathologist.“While these approaches are widely used, they can be time-consuming and don’t always give clear or definitive results,” Vo-Dinh said. “In some cases, patients may have to wait weeks for answers, and the accuracy can vary depending on sampling and interpretation.”The collaborative teams used a technology known as Dynamic Optical Contrast Imaging (DOCI), a technique developed at UCLA, which uses laser light to excite tissue. When exposed to this light, different molecules in the tissue emit fluorescence—subtle signals that vary depending on whether tissue is cancerous or healthy. The result is a color-coded “map” of the tissue that reflects its biological properties.“Instead of looking at one spot on the tissue sample, this technique provides spatial information across the entire tissue region monitored,” Vo-Dinh explained. “You can actually see differences in how cancerous and non-cancerous areas respond to light.”These light-based signals are incredibly rich—but also complex. That’s where machine learning comes in. Vo-Dinh’s team applied machine learning algorithms to analyze the complex imaging data generated by DOCI. The researchers trained AI models to recognize subtle patterns in the imaging data and distinguish between different types of thyroid cancer, specifically papillary and follicular thyroid cancers, and to determine whether tissue was cancerous.The results were promising. The machine learning system showed strong agreement with pathological findings, accurately identifying cancerous regions within the tissue samples.“This is an exciting proof of principle demonstration that combining photonics with AI can work together and provide meaningful, reliable answers,” Vo-Dinh said. “The performance we’re seeing so far is very encouraging.”While the research is still in its early stages, the potential implications for patient care are significant.Because this approach directly analyzes the tissue and does not rely on waiting for lab-based assays, it could eventually support faster, point-of-care cancer assessment. Imagine a future where clinicians may be able to use similar tools directly on tissue, potentially even during surgery, to guide decisions in real time.“It could reduce the need for repeat biopsies and long waiting periods,” Vo-Dinh said. “And because the technique is non-invasive, it may also make screening easier and more accessible for patients.”The work underscores the critical importance of collaboration across institutions and disciplines, bringing together clinical expertise, advanced imaging, and data science.“This is a very synergistic partnership,” Vo-Dinh said. “Each group contributes something essential, from clinical insight to optical technology to computational analysis. That kind of complementarity is what drives innovation.”Next steps will focus on expanding and refining the technology, with the goal of enabling real-time, in situ cancer detection.“We’re excited to continue this collaboration and explore how far this approach can go,” Vo-Dinh said.
The Duke Cancer Institute Supportive Care and Survivorship Center is hosting a new Head & Neck Cancer Support Group. This group is designed to provide a structured and supportive environment for patients and caregivers to connect, share experiences, and access peer-informed resources as part of comprehensive, holistic cancer care.The Head & Neck Cancer Support Group will meet on the second Monday of each month. Geoff Vaughan, a licensed medical family therapist with DCI, will facility these sessions. A medical student-based patient navigation component is currently being developed and will launch in spring 2026.This initiative is supported by the Albert Schweitzer Fellowship, North Carolina Chapter (2025–2026), awarded to Rebecca Zasloff and Alie Hunter, medical students at Duke University School of Medicine and members of the Transdisciplinary Otolaryngology Research, Community Health, and Equity (TORCHE) Lab led by Nosayaba Osazuwa-Peters, PhD. The project has also recently received Duke Bass Connections funding for the 2026–2027 academic year, which will support the continuation and expansion of this work.
